Organon & Co.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Earnings per Share
- Earnings per Share (“EPS”)
The calculations of basic and diluted EPS are as follows:
| Year EndedDecember 31, | |||
|---|---|---|---|
| ($ in millions and shares in thousands, except per share amounts) | 2025 | 2024 | 2023 |
| Net income | $187 | $864 | $1,023 |
| Basic weighted average number of shares outstanding | 259,495 | 257,046 | 255,239 |
| Stock awards and equity units (share equivalent) | 1,269 | 2,106 | 1,031 |
| Diluted weighted average common shares outstanding | 260,764 | 259,152 | 256,270 |
| EPS: | |||
| Basic | $0.72 | $3.36 | $4.01 |
| Diluted | $0.72 | $3.33 | $3.99 |
| Anti-dilutive shares excluded from the calculation of EPS | 12,641 | 8,363 | 9,025 |
Diluted EPS was computed using the treasury stock method for stock option awards, performance share units, and restricted share units. The computation of diluted EPS excludes the effect of the potential exercise of stock-based awards when the effect of the potential exercise would be anti-dilutive.
-78-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.